{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:02:27Z","timestamp":1784037747878,"version":"3.55.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"SATT LINKSIUM GRENOBLE ALPES"},{"name":"NeuroCoG IDEX UGA in the framework of the \u201cInvestissements d'avenir\u201d program","award":["ANR-15-IDEX-02"],"award-info":[{"award-number":["ANR-15-IDEX-02"]}]},{"name":"CBH-EUR-GS","award":["ANR-17-EURE-0003"],"award-info":[{"award-number":["ANR-17-EURE-0003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Soluble oligomeric forms of Tau protein have emerged as crucial players in the propagation of Tau pathology in Alzheimer\u2019s disease (AD). Our objective is to introduce a single-domain antibody (sdAb) named 2C5 as a novel radiotracer for the efficient detection and longitudinal monitoring of oligomeric Tau species in the human brain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The development and production of 2C5 involved llama immunization with the largest human Tau isoform oligomers of different maturation states. Subsequently, 2C5 underwent comprehensive in vitro characterization for affinity and specificity via Enzyme-Linked Immunosorbent Assay and immunohistochemistry on human brain slices. Technetium-99m was employed to radiolabel 2C5, followed by its administration to healthy mice for biodistribution analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>2C5 exhibited robust binding affinity towards Tau oligomers (Kd\u2009=\u20096.280 nM\u2009\u00b1\u20090.557) and to Tau fibers (Kd\u2009=\u20095.024 nM\u2009\u00b1\u20090.453), with relatively weaker binding observed for native Tau protein (Kd\u2009=\u20091791 nM\u2009\u00b1\u20098.714) and amyloid peptide (Kd\u2009&gt;\u200910,000 nM). Remarkably, this SdAb facilitated immuno-histological labeling of pathological forms of Tau in neurons and neuritic plaques, yielding a high-contrast outcome in AD patients, closely mirroring the performance of reference antibodies AT8 and T22. Furthermore, 2C5 SdAb was successfully radiolabeled with 99mTc, preserving stability for up to 6 h post-radiolabeling (radiochemical purity\u2009&gt;\u200993%). However, following intravenous injection into healthy mice, the predominant uptake occurred in kidneys, amounting to 115.32\u2009\u00b1\u20093.67, 97.70\u2009\u00b1\u200943.14 and 168.20\u2009\u00b1\u200934.52% of injected dose per gram (% ID\/g) at 5, 10 and 45 min respectively. Conversely, brain uptake remained minimal at all measured time points, registering at 0.17\u2009\u00b1\u20090.03, 0.12\u2009\u00b1\u20090.07 and 0.02\u2009\u00b1\u20090.01% ID\/g at 5, 10 and 45 min post-injection respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>2C5 demonstrates excellent affinity and specificity for pathological Tau oligomers, particularly in their early stages of oligomerization. However, the current limitation of insufficient blood\u2013brain barrier penetration necessitates further modifications before considering its application in nuclear medicine imaging for humans.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-024-04987-1","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T05:02:49Z","timestamp":1708059769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A single-domain antibody for the detection of pathological Tau protein in the early stages of oligomerization"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0145-259X","authenticated-orcid":false,"given":"Nicolas","family":"De Leiris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Perret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00fclent","family":"G\u00f6zel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Chierici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Millet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marl\u00e8ne","family":"Debiossat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Bacot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin B.","family":"Tournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Chames","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Lenormand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ghezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Fagret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelle","family":"Moulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"4987_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3233\/JAD-161149","volume":"57","author":"M Robinson","year":"2017","unstructured":"Robinson M, Lee BY, Hane FT. Recent progress in Alzheimer\u2019s disease research, part 2: genetics and epidemiology. J Alzheimers Dis. 2017;57:317\u201330.","journal-title":"J Alzheimers Dis"},{"key":"4987_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","volume":"25","author":"CA Lane","year":"2018","unstructured":"Lane CA, Hardy J, Schott JM. Alzheimer\u2019s disease. Eur J Neurol. 2018;25:59\u201370.","journal-title":"Eur J Neurol"},{"key":"4987_CR3","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","volume":"20","author":"B Dubois","year":"2021","unstructured":"Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, et al. Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group. Lancet Neurol. 2021;20:484\u201396.","journal-title":"Lancet Neurol"},{"key":"4987_CR4","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","volume":"70","author":"H Braak","year":"2011","unstructured":"Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960\u20139.","journal-title":"J Neuropathol Exp Neurol"},{"key":"4987_CR5","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1093\/brain\/awv236","volume":"138","author":"H Braak","year":"2015","unstructured":"Braak H, Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer\u2019s disease. Brain. 2015;138:2814\u201333.","journal-title":"Brain"},{"key":"4987_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","volume":"18","author":"H Braak","year":"1997","unstructured":"Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351\u20137.","journal-title":"Neurobiol Aging"},{"key":"4987_CR7","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","volume":"23","author":"MA Busche","year":"2020","unstructured":"Busche MA, Hyman BT. Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease. Nat Neurosci. 2020;23:1183\u201393.","journal-title":"Nat Neurosci"},{"key":"4987_CR8","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1093\/brain\/awz268","volume":"142","author":"CR Jack","year":"2019","unstructured":"Jack CR, Wiste HJ, Botha H, Weigand SD, Therneau TM, Knopman DS, et al. The bivariate distribution of amyloid-\u03b2 and tau: relationship with established neurocognitive clinical syndromes. Brain. 2019;142:3230\u201342.","journal-title":"Brain"},{"key":"4987_CR9","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1007\/s00259-021-05191-9","volume":"48","author":"V Dor\u00e9","year":"2021","unstructured":"Dor\u00e9 V, Krishnadas N, Bourgeat P, Huang K, Li S, Burnham S, et al. Relationship between amyloid and Tau levels and its impact on tau spreading. Eur J Nucl Med Mol Imaging. 2021;48:2225\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4987_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S1474-4422(20)30440-3","volume":"20","author":"J Graff-Radford","year":"2021","unstructured":"Graff-Radford J, Yong KXX, Apostolova LG, Bouwman FH, Carrillo M, Dickerson BC, et al. New insights into atypical Alzheimer\u2019s disease in the era of biomarkers. Lancet Neurol. 2021;20:222\u201334.","journal-title":"Lancet Neurol"},{"key":"4987_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science. 1992;256:184\u20135.","journal-title":"Science"},{"key":"4987_CR12","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1093\/brain\/awac229","volume":"145","author":"JA Tanner","year":"2022","unstructured":"Tanner JA, Iaccarino L, Edwards L, Asken BM, Gorno-Tempini ML, Kramer JH, et al. Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer\u2019s disease. Brain. 2022;145:4489\u2013505.","journal-title":"Brain"},{"key":"4987_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/ana.25410","volume":"85","author":"F Panza","year":"2019","unstructured":"Panza F, Lozupone M, Seripa D, Imbimbo BP. Amyloid-\u03b2 immunotherapy for alzheimer disease: is it now a long shot? Ann Neurol. 2019;85:303\u201315.","journal-title":"Ann Neurol"},{"key":"4987_CR14","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","volume":"21","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele R, van der Kant R, Hansson O. Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials. Lancet Neurol. 2022;21:726\u201334.","journal-title":"Lancet Neurol"},{"key":"4987_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev-neuro-072116-031153","volume":"40","author":"M Goedert","year":"2017","unstructured":"Goedert M, Eisenberg DS, Crowther RA. Propagation of Tau aggregates and neurodegeneration. Annu Rev Neurosci. 2017;40:189\u2013210.","journal-title":"Annu Rev Neurosci"},{"key":"4987_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. 2013;12:357\u201367.","journal-title":"Lancet Neurol"},{"key":"4987_CR17","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1212\/01.WNL.0000063311.58879.01","volume":"60","author":"P Giannakopoulos","year":"2003","unstructured":"Giannakopoulos P, Herrmann FR, Bussi\u00e8re T, Bouras C, K\u00f6vari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer\u2019s disease. Neurology. 2003;60:1495\u2013500.","journal-title":"Neurology"},{"key":"4987_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fnagi.2017.00083","volume":"9","author":"SS Shafiei","year":"2017","unstructured":"Shafiei SS, Guerrero-Mu\u00f1oz MJ, Castillo-Carranza DL. Tau oligomers: cytotoxicity, propagation, and mitochondrial damage. Front Aging Neurosci. 2017;9:83.","journal-title":"Front Aging Neurosci"},{"key":"4987_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.974414","volume":"14","author":"NA Jackson","year":"2022","unstructured":"Jackson NA, Guerrero-Mu\u00f1oz MJ, Castillo-Carranza DL. The prion-like transmission of Tau oligomers via exosomes. Front Aging Neurosci. 2022;14: 974414.","journal-title":"Front Aging Neurosci"},{"key":"4987_CR20","doi-asserted-by":"publisher","first-page":"1255555","DOI":"10.1126\/science.1255555","volume":"349","author":"M Goedert","year":"2015","unstructured":"Goedert M. Neurodegeneration. Alzheimer\u2019s and Parkinson\u2019s diseases: the prion concept in relation to assembled A\u03b2, tau, and \u03b1-synuclein. Science. 2015;349:1255555.","journal-title":"Science"},{"key":"4987_CR21","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.molmed.2015.03.003","volume":"21","author":"JT Pedersen","year":"2015","unstructured":"Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer\u2019s disease. Trends Mol Med. 2015;21:394\u2013402.","journal-title":"Trends Mol Med"},{"key":"4987_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104707","volume":"134","author":"A Bittar","year":"2020","unstructured":"Bittar A, Bhatt N, Kayed R. Advances and considerations in AD tau-targeted immunotherapy. Neurobiol Dis. 2020;134: 104707.","journal-title":"Neurobiol Dis"},{"key":"4987_CR23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.neurol.2022.02.456","volume":"178","author":"N Villain","year":"2022","unstructured":"Villain N. Therapeutic news in Alzheimer\u2019s disease: soon a disease-modifying therapy? Rev Neurol (Paris). 2022;178:437\u201340.","journal-title":"Rev Neurol (Paris)"},{"key":"4987_CR24","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jalz.2012.11.008","volume":"9","author":"C-F Xia","year":"2013","unstructured":"Xia C-F, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer\u2019s disease. Alzheimers Dement. 2013;9:666\u201376.","journal-title":"Alzheimers Dement"},{"key":"4987_CR25","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2967\/jnumed.120.252254","volume":"61","author":"VS Mattay","year":"2020","unstructured":"Mattay VS, Fotenos AF, Ganley CJ, Marzella L. Brain Tau imaging: food and drug administration approval of 18F-flortaucipir injection. J Nucl Med. 2020;61:1411\u20132.","journal-title":"J Nucl Med"},{"key":"4987_CR26","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2217\/nnm.13.86","volume":"8","author":"G Hassanzadeh-Ghassabeh","year":"2013","unstructured":"Hassanzadeh-Ghassabeh G, Devoogdt N, De Pauw P, Vincke C, Muyldermans S. Nanobodies and their potential applications. Nanomedicine (Lond). 2013;8:1013\u201326.","journal-title":"Nanomedicine (Lond)"},{"key":"4987_CR27","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/prot.20378","volume":"59","author":"E Dolk","year":"2005","unstructured":"Dolk E, van Vliet C, Perez JMJ, Vriend G, Darbon H, Ferrat G, et al. Induced refolding of a temperature denatured llama heavy-chain antibody fragment by its antigen. Proteins. 2005;59:555\u201364.","journal-title":"Proteins"},{"key":"4987_CR28","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1074\/jbc.M806889200","volume":"284","author":"C Vincke","year":"2009","unstructured":"Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S, Conrath K. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem. 2009;284:3273\u201384.","journal-title":"J Biol Chem"},{"key":"4987_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.iotech.2020.07.001","volume":"7","author":"M Rashidian","year":"2020","unstructured":"Rashidian M, Ploegh H. Nanobodies as non-invasive imaging tools. Immunooncol Technol. 2020;7:2\u201314.","journal-title":"Immunooncol Technol"},{"key":"4987_CR30","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.3390\/diagnostics11091530","volume":"11","author":"J K\u00fcppers","year":"2021","unstructured":"K\u00fcppers J, K\u00fcrpig S, Bundschuh RA, Essler M, L\u00fctje S. Radiolabeling strategies of nanobodies for imaging applications. Diagnostics (Basel). 2021;11:1530.","journal-title":"Diagnostics (Basel)"},{"key":"4987_CR31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0896-6273(89)90210-9","volume":"3","author":"M Goedert","year":"1989","unstructured":"Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein Tau: sequences and localization in neurofibrillary tangles of Alzheimer\u2019s disease. Neuron. 1989;3:519\u201326.","journal-title":"Neuron"},{"key":"4987_CR32","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/j.1460-2075.1993.tb05665.x","volume":"12","author":"M Novak","year":"1993","unstructured":"Novak M, Kabat J, Wischik CM. Molecular characterization of the minimal protease resistant Tau unit of the Alzheimer\u2019s disease paired helical filament. EMBO J. 1993;12:365\u201370.","journal-title":"EMBO J"},{"key":"4987_CR33","doi-asserted-by":"publisher","first-page":"43223","DOI":"10.1074\/jbc.M112.396176","volume":"287","author":"K Flach","year":"2012","unstructured":"Flach K, Hilbrich I, Schiffmann A, G\u00e4rtner U, Kr\u00fcger M, Leonhardt M, et al. Tau oligomers impair artificial membrane integrity and cellular viability. J Biol Chem. 2012;287:43223\u201333.","journal-title":"J Biol Chem"},{"key":"4987_CR34","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0014-5793(97)01062-4","volume":"414","author":"M Arbabi Ghahroudi","year":"1997","unstructured":"Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 1997;414:521\u20136.","journal-title":"FEBS Lett"},{"key":"4987_CR35","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nprot.2014.039","volume":"9","author":"E Pardon","year":"2014","unstructured":"Pardon E, Laeremans T, Triest S, Rasmussen SGF, Wohlk\u00f6nig A, Ruf A, et al. A general protocol for the generation of Nanobodies for structural biology. Nat Protoc. 2014;9:674\u201393.","journal-title":"Nat Protoc"},{"key":"4987_CR36","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1074\/mcp.O112.025486","volume":"13","author":"K Even-Desrumeaux","year":"2014","unstructured":"Even-Desrumeaux K, Nevoltris D, Lavaut MN, Alim K, Borg J-P, Audebert S, et al. Masked selection: a straightforward and flexible approach for the selection of binders against specific epitopes and differentially expressed proteins by phage display. Mol Cell Proteomics. 2014;13:653\u201365.","journal-title":"Mol Cell Proteomics"},{"key":"4987_CR37","doi-asserted-by":"publisher","first-page":"788","DOI":"10.2967\/jnumed.107.048538","volume":"49","author":"LOT Gainkam","year":"2008","unstructured":"Gainkam LOT, Huang L, Caveliers V, Keyaerts M, Hernot S, Vaneycken I, et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT\/micro-CT. J Nucl Med. 2008;49:788\u201395.","journal-title":"J Nucl Med"},{"key":"4987_CR38","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.2967\/jnumed.123.265593","volume":"64","author":"R Harada","year":"2023","unstructured":"Harada R, Lerdsirisuk P, Shimizu Y, Yokoyama Y, Du Y, Kudo K, et al. Preclinical characterization of the Tau PET Tracer [18F]SNFT-1: comparison of tau PET tracers. J Nucl Med. 2023;64:1495\u2013501.","journal-title":"J Nucl Med"},{"key":"4987_CR39","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S0140-6736(10)61349-9","volume":"377","author":"C Ballard","year":"2011","unstructured":"Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer\u2019s disease. Lancet. 2011;377:1019\u201331.","journal-title":"Lancet"},{"key":"4987_CR40","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"4987_CR41","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.3390\/ijms15034671","volume":"15","author":"A Mietelska-Porowska","year":"2014","unstructured":"Mietelska-Porowska A, Wasik U, Goras M, Filipek A, Niewiadomska G. Tau protein modifications and interactions: their role in function and dysfunction. Int J Mol Sci. 2014;15:4671\u2013713.","journal-title":"Int J Mol Sci"},{"key":"4987_CR42","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1096\/fj.11-199851","volume":"26","author":"CA Lasagna-Reeves","year":"2012","unstructured":"Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, et al. Identification of oligomers at early stages of Tau aggregation in Alzheimer\u2019s disease. FASEB J. 2012;26:1946\u201359.","journal-title":"FASEB J"},{"key":"4987_CR43","doi-asserted-by":"publisher","first-page":"23063","DOI":"10.1074\/jbc.M111.237974","volume":"286","author":"KR Patterson","year":"2011","unstructured":"Patterson KR, Remmers C, Fu Y, Brooker S, Kanaan NM, Vana L, et al. Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J Biol Chem. 2011;286:23063\u201376.","journal-title":"J Biol Chem"},{"key":"4987_CR44","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/srep00700","volume":"2","author":"CA Lasagna-Reeves","year":"2012","unstructured":"Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, et al. Alzheimer brain-derived tau oligomers propagate pathology from endogenous Tau. Sci Rep. 2012;2:700.","journal-title":"Sci Rep"},{"key":"4987_CR45","doi-asserted-by":"publisher","first-page":"11220","DOI":"10.1021\/jp506258g","volume":"118","author":"TD Do","year":"2014","unstructured":"Do TD, Economou NJ, Chamas A, Buratto SK, Shea J-E, Bowers MT. Interactions between amyloid-\u03b2 and tau fragments promote aberrant aggregates: implications for amyloid toxicity. J Phys Chem B. 2014;118:11220\u201330.","journal-title":"J Phys Chem B"},{"key":"4987_CR46","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00259-022-05999-z","volume":"50","author":"J Wang","year":"2023","unstructured":"Wang J, Jin C, Zhou J, Zhou R, Tian M, Lee HJ, et al. PET molecular imaging for pathophysiological visualization in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2023;50:765\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4987_CR47","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1053\/j.semnuclmed.2020.12.004","volume":"51","author":"L Beyer","year":"2021","unstructured":"Beyer L, Brendel M. Imaging of tau pathology in neurodegenerative diseases: an update. Semin Nucl Med. 2021;51:253\u201363.","journal-title":"Semin Nucl Med"},{"key":"4987_CR48","volume":"13","author":"S Roy","year":"2021","unstructured":"Roy S, Banerjee D, Chatterjee I, Natarajan D, Joy MC. The role of 18F-flortaucipir (AV-1451) in the diagnosis of neurodegenerative disorders. Cureus. 2021;13: e16644.","journal-title":"Cureus"},{"key":"4987_CR49","doi-asserted-by":"publisher","first-page":"20S","DOI":"10.2967\/jnumed.121.263196","volume":"63","author":"C Groot","year":"2022","unstructured":"Groot C, Villeneuve S, Smith R, Hansson O, Ossenkoppele R. Tau PET imaging in neurodegenerative disorders. J Nucl Med. 2022;63:20S-26S.","journal-title":"J Nucl Med"},{"key":"4987_CR50","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00259-019-04496-0","volume":"47","author":"R Smith","year":"2020","unstructured":"Smith R, Sch\u00f6ll M, Leuzy A, J\u00f6gi J, Ohlsson T, Strandberg O, et al. Head-to-head comparison of Tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948. Eur J Nucl Med Mol Imaging. 2020;47:342\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4987_CR51","doi-asserted-by":"publisher","first-page":"e231323","DOI":"10.1001\/jamaneurol.2023.1323","volume":"80","author":"R Smith","year":"2023","unstructured":"Smith R, H\u00e4gerstr\u00f6m D, Pawlik D, Klein G, J\u00f6gi J, Ohlsson T, et al. Clinical utility of tau positron emission tomography in the diagnostic workup of patients with cognitive symptoms. JAMA Neurol. 2023;80:e231323.","journal-title":"JAMA Neurol."},{"key":"4987_CR52","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2967\/jnumed.115.171678","volume":"57","author":"ED Hostetler","year":"2016","unstructured":"Hostetler ED, Walji AM, Zeng Z, Miller P, Bennacef I, Salinas C, et al. Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med. 2016;57:1599\u2013606.","journal-title":"J Nucl Med"},{"key":"4987_CR53","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2967\/jnumed.118.209650","volume":"60","author":"TJ Betthauser","year":"2019","unstructured":"Betthauser TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE, et al. In vivo characterization and quantification of neurofibrillary tau PET radioligand 18F-MK-6240 in humans from Alzheimer disease dementia to young controls. J Nucl Med. 2019;60:93\u20139.","journal-title":"J Nucl Med"},{"key":"4987_CR54","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00401-007-0207-8","volume":"113","author":"B Li","year":"2007","unstructured":"Li B, Chohan MO, Grundke-Iqbal I, Iqbal K. Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated Tau. Acta Neuropathol. 2007;113:501\u201311.","journal-title":"Acta Neuropathol"},{"key":"4987_CR55","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1021\/acschemneuro.9b00217","volume":"10","author":"E Dupr\u00e9","year":"2019","unstructured":"Dupr\u00e9 E, Danis C, Arrial A, Hanoulle X, Homa M, Cantrelle F-X, et al. Single domain antibody fragments as new tools for the detection of neuronal tau protein in cells and in mice studies. ACS Chem Neurosci. 2019;10:3997\u20134006.","journal-title":"ACS Chem Neurosci"},{"key":"4987_CR56","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.ymthe.2022.01.009","volume":"30","author":"C Danis","year":"2022","unstructured":"Danis C, Dupr\u00e9 E, Zejneli O, Caillierez R, Arrial A, B\u00e9gard S, et al. Inhibition of tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment. Mol Ther. 2022;30:1484\u201399.","journal-title":"Mol Ther"},{"key":"4987_CR57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","volume":"17","author":"H Kadry","year":"2020","unstructured":"Kadry H, Noorani B, Cucullo L. A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS. 2020;17:69.","journal-title":"Fluids Barriers CNS"},{"key":"4987_CR58","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12987-020-00226-z","volume":"17","author":"Y Wouters","year":"2020","unstructured":"Wouters Y, Jaspers T, De Strooper B, Dewilde M. Identification and in vivo characterization of a brain-penetrating nanobody. Fluids Barriers CNS. 2020;17:62.","journal-title":"Fluids Barriers CNS"},{"key":"4987_CR59","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1096\/fj.11-201384","volume":"26","author":"T Li","year":"2012","unstructured":"Li T, Bourgeois J-P, Celli S, Glacial F, Le Sourd A-M, Mecheri S, et al. Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging. FASEB J. 2012;26:3969\u201379.","journal-title":"FASEB J"},{"key":"4987_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2016.09.019","volume":"243","author":"T Li","year":"2016","unstructured":"Li T, Vandesquille M, Koukouli F, Dudeffant C, Youssef I, Lenormand P, et al. Camelid single-domain antibodies: a versatile tool for in vivo imaging of extracellular and intracellular brain targets. J Control Release. 2016;243:1\u201310.","journal-title":"J Control Release"},{"key":"4987_CR61","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1111\/j.1476-5381.2011.01723.x","volume":"165","author":"G Caljon","year":"2012","unstructured":"Caljon G, Caveliers V, Lahoutte T, Stijlemans B, Ghassabeh GH, Van Den Abbeele J, et al. Using microdialysis to analyse the passage of monovalent nanobodies through the blood-brain barrier. Br J Pharmacol. 2012;165:2341\u201353.","journal-title":"Br J Pharmacol"},{"key":"4987_CR62","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1096\/fj.01-0343fje","volume":"16","author":"A Muruganandam","year":"2002","unstructured":"Muruganandam A, Tanha J, Narang S, Stanimirovic D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J. 2002;16:240\u20132.","journal-title":"FASEB J"},{"key":"4987_CR63","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3390\/biom11081131","volume":"11","author":"E Ruiz-L\u00f3pez","year":"2021","unstructured":"Ruiz-L\u00f3pez E, Schuhmacher AJ. Transportation of single-domain antibodies through the blood-brain barrier. Biomolecules. 2021;11:1131.","journal-title":"Biomolecules"},{"key":"4987_CR64","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1038\/s41467-018-04529-6","volume":"9","author":"N Lipsman","year":"2018","unstructured":"Lipsman N, Meng Y, Bethune AJ, Huang Y, Lam B, Masellis M, et al. Blood-brain barrier opening in Alzheimer\u2019s disease using MR-guided focused ultrasound. Nat Commun. 2018;9:2336.","journal-title":"Nat Commun"},{"key":"4987_CR65","doi-asserted-by":"publisher","first-page":"9180","DOI":"10.1073\/pnas.2002571117","volume":"117","author":"AR Rezai","year":"2020","unstructured":"Rezai AR, Ranjan M, D\u2019Haese P-F, Haut MW, Carpenter J, Najib U, et al. Noninvasive hippocampal blood-brain barrier opening in Alzheimer\u2019s disease with focused ultrasound. Proc Natl Acad Sci U S A. 2020;117:9180\u20132.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-04987-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-04987-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-04987-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T05:05:18Z","timestamp":1708059918000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-04987-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4987"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-04987-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3485065\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"assertion":[{"value":"23 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were performed in accordance with the institutional guidelines and approved by the animal care and use committee of Grenoble University and the ad hoc French minister (n\u00b002573.02).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"These results are covered by an application for a French patent (FR 16 60 450).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}